IGC Pharma, Inc.: IGC Pharma Secures North American Composition Protection for IGC-AD1 as Phase 2 CALMA Enrollment Advances

POTOMAC, MD / ACCESS Newswire / February 17, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), today announced that the Canadian Intellectual Property Office ("CIPO") has issued a ...

TIOBE Index for February 2026: Specialized Languages Gain Ground as Python’s Lead Eases

February 2026 TIOBE Index shows Python still far ahead, C strengthening in second, C# rising, and R holding the top 10 as rankings compress.

Veru Inc.: Veru Reports Fiscal 2026 First Quarter Financial Results and Clinical Program Progress

Phase 2b PLATEAU clinical trial evaluating enobosarm in combination with semaglutide in older patients with obesity on track to initiate this quarter- --Company to host conference call and webcast ...
The Manila Times

Veru Reports Fiscal 2026 First Quarter Financial Results and Clinical Program Progress

Phase 2b PLATEAU clinical trial evaluating enobosarm in combination with semaglutide in older patients with obesity on track ...